---
document_datetime: 2023-09-21 18:43:18
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/intrinsa-epar-procedural-steps-taken-authorisation_en.pdf
document_name: intrinsa-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.537374
conversion_datetime: 2025-12-24 00:11:09.45394
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1 Submission of the dossier

The  applicant  Procter  &amp;  Gamble  Pharmaceuticals  UK,  Ltd  submitted  on  25  October  2004  an application  for  Marketing  Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Intrinsa, through the centralised procedure.

•

- The  Rapporteurs  circulated  an  assessment  Report  concerning  the  Product  Information  to  all CHMP members on 3 May 2006.

The legal basis for this application refers to Article 8.3 of Directive 2001/83/EC, as amended complete and independent application The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: Rapporteur: Tomas P Salmonson Co-Rapporteur: Josef Suko Licensing status: The product was not licensed in any country at the time of submission of the application. 2 Steps taken for the assessment of the product · The application was received by the EMEA on 25 October 2004. · The procedure started on 15 November 2004. · The Rapporteur's first Assessment Report was circulated to all  CHMP  members  on 25  January  2005.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP members on 25 January 2005 · During  the  meeting  on  14-17  March  2005,  the  CHMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 17 March 2005. · The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on 11 November 2005. Responses to the questions raised on the restricted part of the ASMF were submitted by the ASM on 10 November 2005 · The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 29 December 2005. · During the CHMP meeting on 23-26 January 2006, the CHMP agreed on a list of outstanding issues to be addressed in writing and if necessary in an oral explanation by the applicant. · The  applicant submitted the responses to the CHMP  a  list of outstanding issues on 10 March 2006. The Active Substance manufacturer submitted the responses to the outstanding issue relating to the restricted part of the ASMF on 13 March 2006. · The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of outstanding issues to all CHMP members on 31 March 2006. · The Rapporteurs circulated a revised Joint Assessment Report on the applicant's responses to the List of outstanding issues to all CHMP members on 21 April 2006. During the meeting on 24-27 April 2006, the CHMP, in the light of the overall data submitted, the Committee agreed to the applicant's request for 1-month extension of clock-stop in order to allow for finalisation of the Product Information. Medicinal product no longer authorised

- The Rapporteurs circulated a revised assessment Report concerning the Product Information to all CHMP members on 22 May 2006.

<div style=\"page-break-after: always\"></div>

- During  the  meeting  on  29  May  -  1  June  2006,  the  CHMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for granting a Marketing Authorisation to Intrinsa on 1 June 2006. The applicant provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 31 May 2006.
- The  European  Commission  granted  a  marketing  authorisation  valid  throughout  the  European Union for Intrinsa on 28 July 2006.

<!-- image -->